[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100548733":3},{"organization":4,"armGroups":7,"interventions":21,"overallOfficials":41,"centralContacts":45,"locations":51,"responsibleParty":70,"collaborators":73,"id":76,"slug":77,"hasResults":78,"nctId":79,"briefTitle":80,"officialTitle":81,"acronym":82,"eligibilityCriteria":83,"healthyVolunteers":78,"sex":84,"minAge":85,"maxAge":40,"enrollmentInfo":86,"targetDuration":40,"studyType":89,"phases":90,"briefSummary":93,"conditions":94,"keywords":40,"overallStatus":54,"whyStopped":40,"lastUpdateSubmitDate":99,"lastUpdatePostDateStruct":100,"startDateStruct":103,"completionDateStruct":105,"leadSponsor":107,"locationsCount":108},{"fullName":5,"class":6},"Stanford University","OTHER",[8,15],{"label":9,"type":10,"description":11,"interventionNames":12},"Targeted medical therapy","EXPERIMENTAL","1. Epicardial or microvascular coronary spasm: Amlodipine 2.5mg initial dose, 10mg max dose\n2. Coronary microvascular dysfunction: Nebivolol 5mg initial dose, 20mg max dose\n3. Myocardial Bridge: Nebivolol 5mg initial dose, 20mg max dose\n4. Mixed epicardial\u002Fmicrovascular spasm and coronary microvascular dysfunction\u002Fmyocardial bridge: Amlodipine 2.5mg initial dose, 10mg max dose; PLUS Nebivolol 5mg initial dose, 20mg max dose\n\nParticipants will take their assigned therapy after randomization. Weekly person via in-person visit or telephone is performed to uptitrate therapy to the maximally tolerated dose. After 1-3 weeks, the initial drug titration phase is completed and a final dose reached. Participants are then instructed to take the maximally tolerated dose for an additional 4 weeks to the conclusion of the study.",[13,14],"Drug: Amlodipine","Drug: Nebivolol",{"label":16,"type":17,"description":18,"interventionNames":19},"Placebo","PLACEBO_COMPARATOR","1. Epicardial or microvascular coronary spasm: Placebo\n2. Coronary microvascular dysfunction: Placebo\n3. Myocardial Bridge: Placebo\n4. Mixed epicardial\u002Fmicrovascular spasm and coronary microvascular dysfunction\u002Fmyocardial bridge: Placebo\n\nParticipants will take their assigned therapy after randomization. Weekly person via in-person visit or telephone is performed to uptitrate therapy to the maximally tolerated dose. After 1-3 weeks, the initial drug titration phase is completed and a final dose reached. Participants are then instructed to take the maximally tolerated dose for an additional 4 weeks to the conclusion of the study.",[20],"Drug: Placebo",[22,31,37],{"type":23,"name":24,"description":25,"armGroupLabels":26,"otherNames":27},"DRUG","Amlodipine","Amlodipine taken once orally daily at a starting dose of 2.5mg, uptitrated to a maximum of 10mg if tolerated.",[9],[28,29,30],"Norvasc","Katerzia","Norliqva",{"type":23,"name":32,"description":33,"armGroupLabels":34,"otherNames":35},"Nebivolol","Nebivolol taken once orally daily at a starting dose of 5mg, uptitrated to a maximum of 20mg if tolerated.",[9],[36],"Bystolic",{"type":23,"name":16,"description":38,"armGroupLabels":39,"otherNames":40},"Placebo taken once orally daily.",[16],null,[42],{"name":43,"affiliation":5,"role":44},"Jennifer Tremmel, MD","PRINCIPAL_INVESTIGATOR",[46],{"name":47,"role":48,"phone":49,"phoneExt":40,"email":50},"Christopher Wong, MBBS, PhD","CONTACT","(650) 725 5909","ccywong@stanford.edu",[52],{"facility":53,"status":54,"city":55,"state":56,"zip":57,"country":58,"countryCode":59,"cosmosGeoPoint":60,"geoPoint":65,"contacts":66},"Stanford Hospital","RECRUITING","Palo Alto","California","94304","United States","US",{"type":61,"coordinates":62},"Point",[63,64],-122.14302,37.44188,{"lat":64,"lon":63},[67,69],{"name":47,"role":48,"phone":68,"phoneExt":40,"email":50},"650-725-5909",{"name":43,"role":44,"phone":40,"phoneExt":40,"email":40},{"type":44,"investigatorFullName":71,"investigatorTitle":72,"investigatorAffiliation":5,"oldNameTitle":40,"oldOrganization":40},"Christopher Chi-Yuen Wong","Postdoc",[74],{"name":75,"class":6},"American Heart Association","100548733","phase-2-efficacy-of-targeted-medical-therapy-in-angina-and-nonobstructive-coronary-arteries-100548733",false,"NCT06424834","Efficacy of Targeted Medical Therapy in Angina and Nonobstructive Coronary Arteries","A Randomized Controlled Study of Targeted Medical Therapy Versus Placebo for Angina and Non- Obstructive Coronary Arteries: The MVP-ANOCA Study","MVP-ANOCA","Inclusion Criteria:\n\n* All patients with stable angina referred to the Stanford University Hospital cardiac catheterization laboratory for clinically indicated coronary function testing are eligible for inclusion into the study.\n\nSpecific inclusion criteria for randomization:\n\n* Absence of significant epicardial coronary artery disease on angiography\n* Fractional flow reserve \\> 0.80\n\nAnd ≥ 1 of the following:\n\n* Epicardial coronary spasm on acetylcholine testing\n* Microvascular spasm on acetylcholine testing\n* Coronary flow reserve \\\u003C 2.5\n* Index of microcirculatory resistance ≥ 25\n* Myocardial bridge on intravascular ultrasound with dobutamine resting full-cycle ratio ≤ 0.76\n\nExclusion Criteria:\n\n* Acute coronary syndrome less than one week prior to enrolment\n* Cardiomyopathy\n* Contraindications to beta-blockers or calcium channel blockers\n* Baseline systolic blood pressure \\\u003C 95 mmHg\n* Baseline heart rate \\\u003C 55 bpm","ALL","18 Years",{"count":87,"type":88},150,"ESTIMATED","INTERVENTIONAL",[91,92],"PHASE2","PHASE3","The goal of this clinical trial is to learn if targeted medical therapy will improve symptoms and quality of life in patients with angina and non-obstructive coronary arteries compared to placebo, after the underlying cause of the chest pain has been ascertained by coronary function testing.\n\nParticipants will be treated with either medications that target the underlying cause of their chest pain or placebo for 4 weeks after a drug titration phase of 1-3 weeks. They will be asked to complete a series of questionnaires to evaluate their quality of life at the beginning and end of the study.",[95,96,97,98],"Angina Pectoris","Microvascular Angina","Vasospastic Angina","Myocardial Bridge of Coronary Artery","2024-11-26",{"date":101,"type":102},"2024-11-27","ACTUAL",{"date":104,"type":102},"2024-10-10",{"date":106,"type":88},"2026-12",{"name":5,"class":6},1]